Where Is Idiopathic Pulmonary Fibrosis Treatment Going?

Harold R. Collard, MD; Paul J. Wolters, MD


March 22, 2021

FDA approvals in 2014 of two antifibrotic therapies for patients with idiopathic pulmonary fibrosis (IPF) provided clinicians with treatment options proven to slow progression of the chronic, fatal condition. Since then, research has deepened experts' understanding of the underlying senescence-related changes that occur in the biology of afflicted lungs. From that, a subgroup of patients has been identified who suffer from progressive pulmonary fibrosis that worsens despite therapy. More research is needed to arrive at new approaches to identifying and treating patients with this phenotype.

In this ReCAP, Drs Harold Collard and Paul Wolters, of University of California, San Francisco, debate the implications of isolating a new phenotype distinct from IPF but with shared biology. These leading pulmonologists also discuss the role of telomeropathy as a prognostic biomarker for IPF, and they explain the importance of taking a complete family history and extending genetic testing to family members of patients with IPF.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.